SK281472B6 - Použitie lys-plazminogénu na prípravu farmaceutickej kompozície - Google Patents

Použitie lys-plazminogénu na prípravu farmaceutickej kompozície Download PDF

Info

Publication number: SK281472B6
Authority: SK; Slovakia
Prior art keywords: plasminogen; lys; ischemia; reperfusion; reperfusion injury
Prior art date: 1993-07-02

Application number

SK798-94A

Other languages

English (en)

Slovak (sk)

Other versions

SK79894A3 (en

Inventor

Johann Eibl

Ludwig Pichler

Hans-Peter Schwarz

Original Assignee

Baxter Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-02

Filing date

1994-07-01

Publication date

2001-04-09

1994-07-01 Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft

1995-05-10 Publication of SK79894A3 publication Critical patent/SK79894A3/sk

2001-04-09 Publication of SK281472B6 publication Critical patent/SK281472B6/sk

Links

108010087750 lysyl-plasminogen Proteins 0.000 title claims abstract description 83
239000008194 pharmaceutical composition Substances 0.000 title claims description 15
208000028867 ischemia Diseases 0.000 claims abstract description 46
206010063837 Reperfusion injury Diseases 0.000 claims abstract description 31
230000010410 reperfusion Effects 0.000 claims abstract description 27
238000011282 treatment Methods 0.000 claims abstract description 23
230000000302 ischemic effect Effects 0.000 claims abstract description 20
210000000056 organ Anatomy 0.000 claims description 28
208000006011 Stroke Diseases 0.000 claims description 17
238000001356 surgical procedure Methods 0.000 claims description 13
206010008118 cerebral infarction Diseases 0.000 claims description 12
201000006474 Brain Ischemia Diseases 0.000 claims description 9
206010008120 Cerebral ischaemia Diseases 0.000 claims description 9
230000006931 brain damage Effects 0.000 claims description 5
231100000874 brain damage Toxicity 0.000 claims description 5
208000029028 brain injury Diseases 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
208000010125 myocardial infarction Diseases 0.000 claims description 4
230000000451 tissue damage Effects 0.000 claims description 4
231100000827 tissue damage Toxicity 0.000 claims description 4
208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
230000004089 microcirculation Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
102000013566 Plasminogen Human genes 0.000 abstract description 20
108010051456 Plasminogen Proteins 0.000 abstract description 20
229940012957 plasmin Drugs 0.000 abstract description 12
102000004169 proteins and genes Human genes 0.000 abstract description 12
108090000623 proteins and genes Proteins 0.000 abstract description 12
239000000126 substance Substances 0.000 abstract description 7
230000009089 cytolysis Effects 0.000 abstract description 5
230000001681 protective effect Effects 0.000 abstract description 3
230000006337 proteolytic cleavage Effects 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 3
102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract description 2
229960000187 tissue plasminogen activator Drugs 0.000 abstract description 2
210000001519 tissue Anatomy 0.000 description 28
241000700159 Rattus Species 0.000 description 22
210000004369 blood Anatomy 0.000 description 17
239000008280 blood Substances 0.000 description 17
230000000694 effects Effects 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
238000000034 method Methods 0.000 description 15
230000017531 blood circulation Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
239000000872 buffer Substances 0.000 description 9
230000002490 cerebral effect Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
230000007971 neurological deficit Effects 0.000 description 8
108010073385 Fibrin Proteins 0.000 description 7
102000009123 Fibrin Human genes 0.000 description 7
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000006378 damage Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
229950003499 fibrin Drugs 0.000 description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000034994 death Effects 0.000 description 6
231100000517 death Toxicity 0.000 description 6
239000012634 fragment Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
206010048962 Brain oedema Diseases 0.000 description 5
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 5
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 5
208000006752 brain edema Diseases 0.000 description 5
230000020764 fibrinolysis Effects 0.000 description 5
210000003388 posterior cerebral artery Anatomy 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
206010021143 Hypoxia Diseases 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 4
229960000326 flunarizine Drugs 0.000 description 4
230000007954 hypoxia Effects 0.000 description 4
230000003447 ipsilateral effect Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
206010003591 Ataxia Diseases 0.000 description 3
201000004569 Blindness Diseases 0.000 description 3
208000005189 Embolism Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
230000003727 cerebral blood flow Effects 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
206010058990 Venous occlusion Diseases 0.000 description 2
208000012886 Vertigo Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
210000002551 anterior cerebral artery Anatomy 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000004004 carotid artery internal Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
208000004343 lateral medullary syndrome Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000003657 middle cerebral artery Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
239000000758 substrate Substances 0.000 description 2
210000000798 superior sagittal sinus Anatomy 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
210000002385 vertebral artery Anatomy 0.000 description 2
231100000889 vertigo Toxicity 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
206010064012 Central pain syndrome Diseases 0.000 description 1
208000021910 Cerebral Arterial disease Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
208000003164 Diplopia Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000002251 Dissecting Aneurysm Diseases 0.000 description 1
206010049669 Dyscalculia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019013 Haemorrhagic infarction Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
206010058558 Hypoperfusion Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000004404 Intractable Pain Diseases 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
201000000251 Locked-in syndrome Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
235000010676 Ocimum basilicum Nutrition 0.000 description 1
240000007926 Ocimum gratissimum Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000007957 amaurosis fugax Diseases 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
206010002895 aortic dissection Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000010455 autoregulation Effects 0.000 description 1
210000001841 basilar artery Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
230000008822 capillary blood flow Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000000963 caseinolytic effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000004182 chemical digestion Methods 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
206010013932 dyslexia Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
201000010235 heart cancer Diseases 0.000 description 1
208000024348 heart neoplasm Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000019948 ion homeostasis Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
201000002818 limb ischemia Diseases 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229940063121 neoral Drugs 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000007959 normoxia Effects 0.000 description 1
206010029864 nystagmus Diseases 0.000 description 1
210000001636 ophthalmic artery Anatomy 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000009894 physiological stress Effects 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000037047 psychomotor activity Effects 0.000 description 1
230000001179 pupillary effect Effects 0.000 description 1
210000000449 purkinje cell Anatomy 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
208000027765 speech disease Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229940033618 tisseel Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
208000037997 venous disease Diseases 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
230000003462 zymogenic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Farming Of Fish And Shellfish (AREA)
Electrotherapy Devices (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Plant Substances (AREA)
External Artificial Organs (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SK798-94A 1993-07-02 1994-07-01 Použitie lys-plazminogénu na prípravu farmaceutickej kompozície SK281472B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8803393A	1993-07-02	1993-07-02

Publications (2)

Publication Number	Publication Date
SK79894A3 SK79894A3 (en)	1995-05-10
SK281472B6 true SK281472B6 (sk)	2001-04-09

Family

ID=22208925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK798-94A SK281472B6 (sk)	1993-07-02	1994-07-01	Použitie lys-plazminogénu na prípravu farmaceutickej kompozície

Country Status (19)

Country	Link
US (2)	US5520912A (de)
EP (1)	EP0631786B1 (de)
JP (1)	JP2784146B2 (de)
AT (2)	ATE167400T1 (de)
AU (1)	AU680492B2 (de)
CA (1)	CA2127199C (de)
CZ (1)	CZ283352B6 (de)
DE (1)	DE69411084T2 (de)
DK (1)	DK0631786T3 (de)
ES (1)	ES2119934T3 (de)
GR (1)	GR3027778T3 (de)
HR (1)	HRP940381B1 (de)
HU (1)	HU217961B (de)
NO (1)	NO942367L (de)
PL (1)	PL304061A1 (de)
RU (1)	RU2153353C2 (de)
SI (1)	SI0631786T1 (de)
SK (1)	SK281472B6 (de)
ZA (1)	ZA944522B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4411143C2 (de) *	1994-03-30	1996-08-01	Immuno Ag	Thrombosemittel
ATE349226T1 (de) *	1998-09-29	2007-01-15	Leuven Res & Dev Vzw	Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
EP1062953A1 (de) *	1999-06-22	2000-12-27	Leuven Research & Development vzw	Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle
WO2000041714A1 (en) *	1999-01-19	2000-07-20	Bristol-Myers Squibb Company	Method for determining care and prevention pathways for clinical management of wounds
US7184963B1 (en)	1999-01-19	2007-02-27	Bristol-Myers Squibb Company	Method for determining care and prevention pathways for clinical management of wounds
AU3173301A (en) *	2000-02-11	2001-08-20	European Molecular Biology Laboratory	Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
US20050124036A1 (en) *	2002-02-06	2005-06-09	Rudy Susilo	Method for producing recombinant proteins in micro-organisms
AU2003252039A1 (en) *	2002-07-23	2004-02-09	Vegenics Limited	Methods and compositions for activating or inhibiting vegf-d and vegf-c
PE20050438A1 (es) *	2003-10-20	2005-06-14	Esperion Therapeutics Inc	Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
RU2341256C1 (ru) *	2007-03-26	2008-12-20	Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава	Способ профилактики реперфузионных осложнений у пациентов, оперированных по поводу хронической ишемии нижних конечностей
RU2411911C1 (ru) *	2009-07-02	2011-02-20	Клиника государственного образовательного учреждения высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"(Клиника ГОУ ВПО ЧелГМА Роздрава)	Способ прогнозирования характера течения реперфузионного синдрома после поэтапного хирургического лечения сонных артерий у пациентов с симптомными бикаротидными стенозами
KR20120050442A (ko)	2009-07-10	2012-05-18	쓰롬보제닉스 엔.브이.	플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en)	2009-08-28	2012-07-26	Thrombogenics Nv	Improvement to trabeculectomy
EP2661493B1 (de)	2011-01-05	2016-03-30	ThromboGenics N.V.	Plasminogen- und plasminvarianten
JP6000353B2 (ja)	2011-08-12	2016-09-28	スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓＮＶ	プラスミノーゲンおよびプラスミンの変異体
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
TWI677348B (zh) *	2016-12-15	2019-11-21	大陸商深圳瑞健生命科學研究院有限公司	一種改善心臟病變的方法
WO2018107686A1 (zh)	2016-12-15	2018-06-21	深圳瑞健生命科学研究院有限公司	一种治疗动脉粥样硬化及其并发症的方法
JP7168990B2 (ja)	2016-12-15	2022-11-10	タレンゲンインターナショナルリミテッド	肥満症を予防および治療するための方法および薬物
TWI868051B (zh) *	2017-06-23	2025-01-01	美商波麥堤克生物治療股份有限公司	與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
RU2729788C2 (ru) *	2018-09-04	2020-08-12	Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук"	Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника
AU2020212404B2 (en)	2019-01-24	2025-11-27	Previpharma Consulting Gmbh	Plasminogen for treating and preventing microthrombosis
SG11202110554YA (en) *	2019-04-12	2021-10-28	Uglk Science Ab	Method and apparatus for reconditioning kidneys
SG11202110553PA (en) *	2019-04-12	2021-10-28	Uglx Res Ab	Method and apparatus for reconditioning organs
CN114642722A (zh) *	2020-12-18	2022-06-21	四川大学华西医院	纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0028489B1 (de) *	1979-11-05	1983-10-05	Beecham Group Plc	Enzym-Derivate und ihre Herstellung
DE3715662A1 (de) *	1986-05-12	1987-11-19	Wellcome Found	Neue pharmazeutische anwendung
JP2764264B2 (ja) *	1987-10-01	1998-06-11	株式会社ミドリ十字	線溶活性増強剤
US5084274A (en) *	1987-11-17	1992-01-28	Scripps Clinic And Research Foundation	Inhibition of arterial thrombotic occlusion or thromboembolism
US5256642A (en) *	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AT390801B (de) *	1988-07-28	1990-07-10	Immuno Ag	Verfahren zur herstellung von lys-plasminogen
US5358936A (en) *	1990-08-03	1994-10-25	Paul Gordon	Anionic furanose derivatives, methods of making and using the same
AT402367B (de) *	1990-10-11	1997-04-25	Immuno Ag	Pharmazeutische zubereitung auf basis von lys-plasminogen

1994
- 1994-06-08 US US08/257,626 patent/US5520912A/en not_active Expired - Fee Related
- 1994-06-21 NO NO942367A patent/NO942367L/no not_active Application Discontinuation
- 1994-06-22 AU AU64854/94A patent/AU680492B2/en not_active Ceased
- 1994-06-23 ZA ZA944522A patent/ZA944522B/xx unknown
- 1994-06-30 PL PL94304061A patent/PL304061A1/xx unknown
- 1994-06-30 CA CA002127199A patent/CA2127199C/en not_active Expired - Fee Related
- 1994-07-01 HU HU9401983A patent/HU217961B/hu not_active IP Right Cessation
- 1994-07-01 HR HR08/088,033A patent/HRP940381B1/xx not_active IP Right Cessation
- 1994-07-01 EP EP94110267A patent/EP0631786B1/de not_active Expired - Lifetime
- 1994-07-01 SK SK798-94A patent/SK281472B6/sk unknown
- 1994-07-01 CZ CZ941613A patent/CZ283352B6/cs not_active IP Right Cessation
- 1994-07-01 DE DE69411084T patent/DE69411084T2/de not_active Expired - Fee Related
- 1994-07-01 AT AT94110267T patent/ATE167400T1/de not_active IP Right Cessation
- 1994-07-01 DK DK94110267T patent/DK0631786T3/da active
- 1994-07-01 SI SI9430143T patent/SI0631786T1/xx unknown
- 1994-07-01 AT AT0131094A patent/AT407706B/de not_active IP Right Cessation
- 1994-07-01 ES ES94110267T patent/ES2119934T3/es not_active Expired - Lifetime
- 1994-07-01 RU RU94022754/14A patent/RU2153353C2/ru active
- 1994-07-01 JP JP6150797A patent/JP2784146B2/ja not_active Expired - Fee Related
- 1994-11-21 US US08/345,468 patent/US5597800A/en not_active Expired - Fee Related
1998
- 1998-08-31 GR GR980401956T patent/GR3027778T3/el unknown

Also Published As

Publication number	Publication date
AT407706B (de)	2001-05-25
RU94022754A (ru)	1996-08-10
ZA944522B (en)	1995-02-23
NO942367L (no)	1995-01-03
HRP940381B1 (en)	1999-06-30
HU9401983D0 (en)	1994-09-28
US5597800A (en)	1997-01-28
CZ161394A3 (en)	1995-01-18
JPH07145076A (ja)	1995-06-06
ATE167400T1 (de)	1998-07-15
SI0631786T1 (en)	1998-10-31
HUT67225A (en)	1995-03-28
SK79894A3 (en)	1995-05-10
US5520912A (en)	1996-05-28
GR3027778T3 (en)	1998-11-30
NO942367D0 (de)	1994-06-21
CZ283352B6 (cs)	1998-03-18
CA2127199C (en)	2000-11-28
DK0631786T3 (da)	1999-04-06
PL304061A1 (en)	1995-01-09
AU6485494A (en)	1995-01-12
ATA131094A (de)	2000-10-15
HRP940381A2 (en)	1997-04-30
JP2784146B2 (ja)	1998-08-06
ES2119934T3 (es)	1998-10-16
RU2153353C2 (ru)	2000-07-27
DE69411084D1 (de)	1998-07-23
AU680492B2 (en)	1997-07-31
CA2127199A1 (en)	1995-01-03
EP0631786B1 (de)	1998-06-17
HU217961B (hu)	2000-05-28
EP0631786A1 (de)	1995-01-04
DE69411084T2 (de)	1998-12-03

Publication	Publication Date	Title
SK281472B6 (sk)	2001-04-09	Použitie lys-plazminogénu na prípravu farmaceutickej kompozície
AU623423B2 (en)	1992-05-14	A method for preventing tissue damage after an ischemic episode
DE3617753C2 (de)	1988-06-30
Thomas et al.	1990	Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator
EP0451880A2 (de)	1991-10-16	Zusammensetzung zur Perfusion von ex-vivo-Gewebe und die Anwendung derselben
Ahuja et al.	2021	Priapism and sickle cell disease: special considerations in etiology, management, and prevention
Weaver et al.	1994	New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction
JP2012505154A (ja)	2012-03-01	ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
DE3715662A1 (de)	1987-11-19	Neue pharmazeutische anwendung
Sugimori et al.	2001	Intravenous basic fibroblast growth factor produces a persistent reduction in infarct volume following permanent focal ischemia in rats
Jampol et al.	1980	Peripheral proliferative retinopathies
Unal et al.	2000	The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment
Campbell et al.	1974	Effects of antifibrinolytic and steroid therapy on the contused spinal cord of cats
Garcia et al.	1981	Arterial air embolism: structural effects on the gerbil brain.
KR101556812B1 (ko)	2015-10-01	하부 요로 질환 치료제 및 하부 요로 증상 개선제
EP1057489B1 (de)	2007-01-03	Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
TREMPER et al.	1985	Clinical experience with Fluosol-DA (20%) in the United States
JPH0912475A (ja)	1997-01-14	虚血−再灌流障害の予防および治療薬
Hecker et al.	1961	Central retinal artery occlusion successfully treated with plasmin
Hund et al.	1995	Neurocritical care for acute ischemic stroke
US8106009B2 (en)	2012-01-31	Pharmaceutical composition for preventing or treating ischemic diseases
JP3113787B2 (ja)	2000-12-04	脳梗塞予防治療剤
Digiacinto et al.	1970	Influence of hypertension on postischemic cerebrovascular obstruction
Newton	2008	An Evidence-Based Review of the Neurological Applications of Hyperbaric Oxygen Therapy. Part 1
RU2021124857A (ru)	2023-02-27	Плазминоген для лечения и профилактики микротромбоза